Company record · VYNE · Pharmaceutical Preparations
Yarrow Bioscience, Inc.
Yarrow Bioscience, Inc.'s chief financial officer on the record is Tyler Zeronda, effective July 27, 2026, per the filing record.
The record holds 1 verified CFO change for Yarrow Bioscience, Inc. from Form 8-K filings, filed July 28, 2026 and its 10-K filed February 27, 2026, where no CFO signature could be established.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Tyler Zeronda |
| Title as printed | Chief Financial Officer |
| Basis | Latest move: transition, 8-K filed July 28, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-28Transition
Yarrow Bioscience, Inc. CFO transition: Tyler Zeronda to succeed Mutya Harscheffective July 27, 2026 · 8-K filed July 28, 2026 · sec.gov, Item 5.02
2026-02-2710-K signature
CFO signature not established from the annual report
10-K filed February 27, 2026 · sec.gov
Company
| Ticker | VYNE |
|---|---|
| SEC CIK | 0001566044 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | From the 10-K filed 2026-02-27: no principal financial officer among the signers (No signer with the title "Chief Financial Officer" or "Principal Financial Officer" appears in the provided SIGNATURES section. The only signer present is David Domzalski, whose title is Chief Executive Officer.). |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.